Clinical Trials Browser

OTHER × Interventional × entrectinib × Clear all

NCT06528691 2026-04-22

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase 2 Recruiting

Glioma, Central Nervous System Neoplasms

NCT03994796 2026-04-13

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Phase 2 Active not recruiting

Brain Neoplasms, Neoplasm Metastasis

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT05770544 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSDermatologicLymphoidOther hematologic neoplasm

Brain Neoplasms, Glioma, Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT05396859 2025-10-20

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Phase 4 Recruiting

EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2 Recruiting

Locally Advanced Thyroid Gland Carcinoma

NCT04551495 2024-12-04

ROSALINE

Phase 2 Active not recruiting

Carcinoma, Lobular

NCT06692491 2024-11-18

SPRING

Phase 2 Not yet recruiting

Rare Tumour

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05159245 2024-07-15

FINPROVE

Phase 2 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04817956 2024-02-29

IMPRESS-N

Phase 2 Recruiting

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04589832 2023-11-22

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Phase 1/2 Terminated

6 enrolled 9 charts

Uveal Melanoma

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Phase 2 Terminated

1 enrolled 7 charts

Noonan Syndrome 6, Melanoma